These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

337 related articles for article (PubMed ID: 11825326)

  • 21. Gemcitabine doublets in advanced pancreatic cancer: should we move on?
    Rocha Lima CM; Flores AM
    J Clin Oncol; 2006 Jan; 24(3):327-9. PubMed ID: 16344312
    [No Abstract]   [Full Text] [Related]  

  • 22. A randomised phase II study of modified FOLFIRI.3 vs modified FOLFOX as second-line therapy in patients with gemcitabine-refractory advanced pancreatic cancer.
    Yoo C; Hwang JY; Kim JE; Kim TW; Lee JS; Park DH; Lee SS; Seo DW; Lee SK; Kim MH; Han DJ; Kim SC; Lee JL
    Br J Cancer; 2009 Nov; 101(10):1658-63. PubMed ID: 19826418
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment of metastatic pancreatic cancer.
    Ko AH; Tempero MA
    J Natl Compr Canc Netw; 2005 Sep; 3(5):627-36. PubMed ID: 16194454
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Irinotecan combined with gemcitabine, 5-fluorouracil, leucovorin, and cisplatin (G-FLIP) is an effective and noncrossresistant treatment for chemotherapy refractory metastatic pancreatic cancer.
    Kozuch P; Grossbard ML; Barzdins A; Araneo M; Robin A; Frager D; Homel P; Marino J; DeGregorio P; Bruckner HW
    Oncologist; 2001; 6(6):488-95. PubMed ID: 11743211
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Docetaxel in the management of advanced pancreatic cancer.
    Lopes G; Rocha Lima CM
    Semin Oncol; 2005 Apr; 32(2 Suppl 4):S10-23. PubMed ID: 16015551
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Chemotherapeutic gemcitabine doublets in pancreatic carcinoma.
    Richards DA
    Semin Oncol; 2005 Aug; 32(4 Suppl 6):S9-13. PubMed ID: 16143162
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Gemcitabine in the treatment of advanced pancreatic cancer: a comparative analysis of randomized trials.
    Heinemann V
    Semin Oncol; 2002 Dec; 29(6 Suppl 20):9-16. PubMed ID: 12577228
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Chemotherapy for advanced pancreatic cancer.
    Haller DG
    Int J Radiat Oncol Biol Phys; 2003; 56(4 Suppl):16-23. PubMed ID: 12826247
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Contribution of gemcitabine in the treatment of advanced pancreatic cancer].
    Brunet R; Fonck M
    Rev Med Interne; 1999 Sep; 20(9):816-20. PubMed ID: 10522306
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Gemcitabine and pancreatic cancer].
    Prost P; Ychou M; Azria D
    Bull Cancer; 2002 Aug; 89 Spec No():S91-5. PubMed ID: 12449037
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Second-line therapy in gemcitabine-pretreated patients with advanced pancreatic cancer.
    Boeck S; Heinemann V
    J Clin Oncol; 2008 Mar; 26(7):1178-9; author reply 1179. PubMed ID: 18309957
    [No Abstract]   [Full Text] [Related]  

  • 32. Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial.
    Kunzmann V; Siveke JT; Algül H; Goekkurt E; Siegler G; Martens U; Waldschmidt D; Pelzer U; Fuchs M; Kullmann F; Boeck S; Ettrich TJ; Held S; Keller R; Klein I; Germer CT; Stein H; Friess H; Bahra M; Jakobs R; Hartlapp I; Heinemann V;
    Lancet Gastroenterol Hepatol; 2021 Feb; 6(2):128-138. PubMed ID: 33338442
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Future directions in the treatment of pancreatic cancer.
    Haller DG
    Semin Oncol; 2002 Dec; 29(6 Suppl 20):31-9. PubMed ID: 12577231
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Concurrent chemoradiation therapy with gemcitabine for advanced or relapsed pancreatic tumors].
    Ioka T; Nakaizumi A; Tanaka S; Yamazaki H; Nishiyama K
    Nihon Rinsho; 2006 Jan; 64 Suppl 1():248-53. PubMed ID: 16457260
    [No Abstract]   [Full Text] [Related]  

  • 35. [Updates on gemcitabine at the American Society of Clinical Oncology congress (ASCO, 2002) ].
    Gligorov J; André T; Epaud C; Culine S
    Bull Cancer; 2002 Aug; 89 Spec No():S134-44. PubMed ID: 12449045
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial.
    Regine WF; Winter KA; Abrams RA; Safran H; Hoffman JP; Konski A; Benson AB; Macdonald JS; Kudrimoti MR; Fromm ML; Haddock MG; Schaefer P; Willett CG; Rich TA
    JAMA; 2008 Mar; 299(9):1019-26. PubMed ID: 18319412
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Locally advanced unresectable pancreatic cancer: Induction chemoradiotherapy followed by maintenance gemcitabine versus gemcitabine alone: Definitive results of the 2000-2001 FFCD/SFRO phase III trial].
    Barhoumi M; Mornex F; Bonnetain F; Rougier P; Mariette C; Bouché O; Bosset JF; Aparicio T; Mineur L; Azzedine A; Hammel P; Butel J; Stremsdoerfer N; Maingon P; Bedenne L; Chauffert B
    Cancer Radiother; 2011 Jun; 15(3):182-91. PubMed ID: 21315644
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Gemcitabine chemotherapy versus 5-fluorouracil-based concurrent chemoradiotherapy in locally advanced unresectable pancreatic cancer.
    Park JK; Ryu JK; Lee JK; Yoon WJ; Lee SH; Kim YT; Yoon YB
    Pancreas; 2006 Nov; 33(4):397-402. PubMed ID: 17079946
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Gemzar (gemcitabine)--a new chemotherapeutic agent for pancreatic cancer].
    Merimsky O; Chaitchik S
    Harefuah; 1997 Sep; 133(5-6):208-12. PubMed ID: 9461693
    [No Abstract]   [Full Text] [Related]  

  • 40. Pancreatic cancer: highlights from the 42nd annual meeting of the American Society of Clinical Oncology, 2006.
    Saif MW
    JOP; 2006 Jul; 7(4):337-48. PubMed ID: 16832131
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.